Welcome to the InfoSci Platform
Hashimoto's Encephalopathy

Hashimoto's Encephalopathy

Copyright: © 2020 |Pages: 15
ISBN13: 9781522596554|ISBN10: 1522596550|ISBN13 Softcover: 9781522596561|EISBN13: 9781522596578
DOI: 10.4018/978-1-5225-9655-4.ch009
Cite Chapter Cite Chapter

MLA

Mahmoud Sakr. "Hashimoto's Encephalopathy." Diagnosing and Managing Hashimoto’s Disease: Emerging Research and Opportunities, IGI Global, 2020, pp.126-140. https://doi.org/10.4018/978-1-5225-9655-4.ch009

APA

M. Sakr (2020). Hashimoto's Encephalopathy. IGI Global. https://doi.org/10.4018/978-1-5225-9655-4.ch009

Chicago

Mahmoud Sakr. "Hashimoto's Encephalopathy." In Diagnosing and Managing Hashimoto’s Disease: Emerging Research and Opportunities. Hershey, PA: IGI Global, 2020. https://doi.org/10.4018/978-1-5225-9655-4.ch009

Export Reference

Mendeley
Favorite

Abstract

Hashimoto's encephalopathy is a relapsing encephalopathy occurring in association with Hashimoto's thyroiditis (HT) with high titers of anti-thyroid antibodies. The mechanism of pathogenesis is unknown. Auto-antibodies to α-enolase have been found to be associated with Hashimoto's encephalopathy. Recently, the crucial role of neuro-inflammation in the development of psychological disorders including depression and anxiety has received more attention. Because the majority of patients with Hashimoto's encephalopathy respond to steroids or immuno-suppressant treatment, this condition is now also referred to as “steroid-responsive encephalopathy.” Initial treatment is usually with oral prednisone (50–150 mg/day) or high-dose IV methyl-Prednisolone (1 g/day) for 3-7 days. Thyroid hormone treatment is also included if required. This chapter explores Hashimoto's encephalopathy.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.